Xilio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	53.48	43.77	6.34	-	-	-
Revenue Growth	476.71%	589.88%	-	-	-	-
Gross Profit	53.48	43.77	6.34	-	-	-
Selling, General & Admin	28.12	29.71	24.78	27	29.95	23.86
Research & Development	67.61	56.04	41.21	52.14	59.2	51.19
Other Operating Expenses	-	-	0.94	-	-	-
Total Operating Expenses	95.73	85.75	66.93	79.13	89.15	75.04
Operating Income	-42.24	-41.98	-60.58	-79.13	-89.15	-75.04
Other Non-Operating Income (Expense)	8.74	6.95	2.34	2.73	0.93	-0.76
Total Non-Operating Income (Expense)	10.94	6.95	2.34	2.73	0.93	-0.76
Pretax Income	-31.3	-35.04	-58.24	-76.4	-88.22	-75.8
Net Income	-31.3	-35.04	-58.24	-76.4	-88.22	-75.8
Net Income to Common	-31.3	-35.04	-58.24	-76.4	-88.22	-75.8
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	11	8	4	2	2	0
Shares Outstanding (Diluted)	12	8	4	2	2	0
Shares Change	149.03%	118.70%	94.61%	0.38%	388.59%	970.34%
EPS (Basic)	-3.40	-4.19	-15.24	-38.92	-45.08	-189.28
EPS (Diluted)	-3.55	-4.19	-15.24	-38.92	-45.08	-189.28
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-57.37	-5.51	-18.41	-69.11	-77.59	-81.85
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-4.95	-0.66	-4.82	-35.19	-39.66	-204.40
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-78.98%	-95.92%	-954.95%	-	-	-
Profit Margin	-58.52%	-80.05%	-918.05%	-	-	-
FCF Margin	-107.26%	-12.59%	-290.26%	-	-	-
EBITDA	-40.86	-40.44	-58.94	-77.23	-87.3	-73.55
EBITDA Margin	-76.39%	-92.40%	-929.03%	-	-	-
EBIT	-42.24	-41.98	-60.58	-79.13	-89.15	-75.04
EBIT Margin	-78.98%	-95.92%	-954.95%	-	-	-

SEC Filings: 10-K · 10-Q